A review of the first step of the National Alliance of Healthcare Purchaser Coalitions’ (NAHPC) 4 key action steps to promote biosimilar uptake.
Transcript
Mohannad Kusti, MD, MPH: I would like also to mention that the National Alliance of HealthcarePurchaser Coalitions [NAHPC] had published an action brief, I believe this was in July 2018, and it was specifically about the value of biosimilars and improving treatment access and lowering cost nationwide. In that document, there were 4 action steps for employers to promote biosimilar uptake.
In this document that I mentioned from the NAHPC, the action steps for employers, the first one is to quantify the biosimilar opportunity by initiating conversations within vendors such as the health plans, the pharmacy benefit managers [PBMs], and the specialty pharmacy provider. This discussion will help initiate a better understanding of the fill rates, the potential savings from utilizing biologicals versus biosimilars, and also the availability of the biosimilars to the members covered under the plan.
Part of step 1, as I mentioned, was to have that understanding of fill rates and savings potential. I would recommend the employers start talking to their account manager, executive account manager for their PBM vendor, and also discuss this if the employer has a pharmacy benefit consultant. That would be another resource for the employer to go to and have these detailed discussions. These can differ between states, regions, and different industries, so I think it’s a very important conversation to be had on specifics and on a case-by-case basis.
Another resource for talking about these things is if the employer belongs to any of the employers’ coalitions or employer health care purchaser coalitions, that would be another resource for employers to reach out to and have these discussions and talk to those on the teams to assist with a better understanding.
Part of that step 1 is to have a better understanding on the opportunities and how they vary between different employers who are self-insured and self-pay versus employers who are commercially insured, because these health plans are handled in a very different manner. Employers who are self-insured may have a lot more control on the benefit design, what is covered under their formulary, and how to make it available to their lives covered, versus the employers who are not self-insured. Those not self-insured have commercial insurance and may not have as much ability to make changes to the plan.
Reducing Low-Value Care Is Hard, but What About Just Not Paying for It?
March 14th 2024After years of efforts to reduce low-value care, panelists at the 2024 Value-Based Insurance Design Summit proposed a new strategy: drawing a line in the sand that payers will not be on the hook for these services.
Read More
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
Retaining Health Care Workers Starts With Insights on “How We Can Stop Breaking Them”
March 2nd 2024Friday's keynote speaker, Katherine A. Meese, PhD, addressed the conference theme of workforce support at the Association of Cancer Care Centers 50th Annual Meeting and Cancer Center Business Summit.
Read More
Drug Prices and OOP Costs Increased Beyond Inflation Rates 2009-2018, But Were Not Related
January 31st 2024Drug prices in the US increased 4.4% annually and median out-of-pocket (OOP) costs increased 9.6% annually from 2009 to 2018, but there was no direct link between these amounts for individual drugs.
Read More
Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024
January 14th 2024Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.
Read More